ZEPOSIA Drug Patent Profile

Which patents cover Zeposia, and what generic alternatives are available?

Zeposia is a drug marketed by Bristol and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty patent family members in thirty-four countries.

The generic ingredient in ZEPOSIA is ozanimod hydrochloride. One supplier is listed for this compound. Additional details are available on the ozanimod hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zeposia

Zeposia was eligible for patent challenges on March 25, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 24, 2033. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEPOSIA

International Patents:	180
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	3
Patent Applications:	61
Drug Prices:	Drug price information for ZEPOSIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEPOSIA
What excipients (inactive ingredients) are in ZEPOSIA?	ZEPOSIA excipients list
DailyMed Link:	ZEPOSIA at DailyMed

See drug prices for ZEPOSIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEPOSIA

NDA:

209899

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEPOSIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	PHASE4
Geert D'Haens	Phase 4
Bristol-Myers Squibb	Phase 4

See all ZEPOSIA clinical trials

Pharmacology for ZEPOSIA

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

US Patents and Regulatory Information for ZEPOSIA

ZEPOSIA is protected by six US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-003	Mar 25, 2020		RX	Yes	Yes			Y	Y
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-003	Mar 25, 2020		RX	Yes	Yes
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No			Y	Y
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-002	Mar 25, 2020		RX	Yes	No

International Patents for ZEPOSIA

When does loss-of-exclusivity occur for ZEPOSIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEPOSIA around the world.

Country	Patent Number	Title	Estimated Expiration
China	102724880
Croatia	P20210446
Japan	2016041736
Mexico	2012005562
South Korea	20110010777
Australia	2009258242	Novel modulators of sphingosine phosphate receptors

Supplementary Protection Certificates for ZEPOSIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2913326	C20200031 00353	Estonia		PRODUCT NAME: OSANIMOOD;REG NO/DATE: EU/1/20/1442 25.05.2020
2291080	2090039-5	Sweden		PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; REG. NO/DATE: EU/1/20/1442 20200525
2498610	PA2020533	Lithuania		PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520
2291080	C202030049	Spain		PRODUCT NAME: OZANIMOD O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE OZANIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/20/1442; DATE OF AUTHORISATION: 20200520; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1442; DATE OF FIRST AUTHORISATION IN EEA: 20200520
2291080	CR 2020 00047	Denmark		PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200525
2498610	20C1059	France		PRODUCT NAME: OZANIMOD OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER CHLORHYDRATE D'OZANIMOD; REGISTRATION NO/DATE: EU/1/20/1442 20200525

Market Dynamics and Financial Trajectory for Zeposia (Ozanimod)

Last updated: January 2, 2026

Executive Summary

Zeposia (ozanimod) is a sphingosine 1-phosphate (S1P) receptor modulator approved by the U.S. Food and Drug Administration (FDA) in March 2020 for relapsing forms of multiple sclerosis (MS) and in May 2021 for ulcerative colitis (UC). Developed by Bristol-Myers Squibb (BMS), Zeposia represents a strategic move into the competitive MS and inflammatory bowel disease (IBD) therapies market.

This report analyzes the market dynamics influencing Zeposia's adoption, competitive positioning, revenue forecasts, and prospects within the current pharmaceutical landscape. Emphasis is placed on the drug's clinical profile, regulatory environment, competitive landscape, pricing strategies, payer coverage, and global expansion potential.

---

1. Understanding Zeposia: Profile and Clinical Indications

Feature	Details
Generic Name	Ozanimod
Brand Name	Zeposia
Therapeutic Class	S1P receptor modulator
Indications Approved	- Multiple Sclerosis (MS): Relapsing forms (RMS), including relapsing-remitting MS (RRMS)
	- Ulcerative Colitis (UC)
Approval Dates	FDA: March 2020 (MS), May 2021 (UC)
Mechanism of Action	Modulates S1P receptors, sequestering lymphocytes in lymph nodes, reducing neuroinflammation and intestinal inflammation

Clinical Highlights:

• Efficacy: Demonstrates significant reduction in annualized relapse rate and MRI lesions in MS; reduces UC symptoms.
• Safety Profile: Improved safety over first-generation S1P receptor modulators like fingolimod, with lower risk of cardiovascular events due to selective receptor affinity.

---

2. Market Dynamics Influencing Zeposia

2.1. Competitive Landscape in MS and UC Markets

Competitors	Indications	Market Share (Approximate, 2022)	Key Features/Differences
Novartis – Gilenya (fingolimod)	MS	40-45%	First oral S1P modulator, higher safety concerns
Biogen – Tysabri (natalizumab)	MS, highly effective, IV	15-20%	High efficacy but higher risks (PML)
Eli Lilly – Olumiant (baricitinib)	MS, IBD (off-label/exploratory)	<5%	JAK inhibitor, different mechanism
Janssen – Stelara (ustekinumab)	UC, Crohn’s	25-30%	Inflammatory pathway targeting; alternative for UC

Zeposia’s Position:

• As a selective, oral therapy with favorable safety, it is positioned as a preferred option for patients intolerant to or inadequately controlled by existing therapies.
• Its approval for UC as a second-line therapy strengthens its market potential.

2.2. Regulatory and Market Access Factors

• FDA Approval: Validates efficacy and safety, crucial for market entry.
• Pricing Strategy: Priced akin to other oral MS therapies (~$80,000 - $90,000/year), with discounts negotiated via formulary access.

Payer Coverage	Status
Commercial insurers, Medicare Advantage, Medicaid managed care	Generally favorable, with some prior authorization requirements

• Reimbursement Landscape: Favorable, as Zeposia's safety profile mitigates concerns leading to rapid formulary placement in the US.
• Global Regulatory Approvals: Approved in the EU (September 2021), Japan (2022). Market penetration outside the US is growing but remains secondary to established brands.

2.3. Market Penetration and Adoption Trends

Parameter	Data/Trend	Impact
Market Penetration (2022)	Estimated 10-15% share of oral MS market	Early adoption phase. Growth potential as physicians become familiar with data
Patient Pool (US MS)	~1.2 million with MS (National MS Society, 2022)	Significant unmet needs for safer oral options
UC Prevalence (US)	~1.3 million with UC (CDC, 2022)	Expansion into UC offers additional revenue channel

---

3. Financial Trajectory of Zeposia

3.1. Revenue Projections

Year	Estimated Sales (USD Millions)	Assumptions
2022	$350 - $400	Initial uptake, growing as label expands and payer coverage increases
2023	$600 - $700	Expanded indications, increased prescriber familiarity, and global approval
2024	$1,000+	Further market penetration, added geographic markets, and competitive positioning

3.2. Revenue Drivers

• Market Expansion: Entry into European and Asian markets.
• Line Extensions: Potential future formulations or combinations.
• Patient Persistence: Chronic disease nature ensures recurring revenue.
• Pricing and Reimbursement: Negotiations and value-based agreements will influence net revenue.

3.3. Cost Structure and Profitability

Aspect	Details
Development & Regulatory	~$500 million in total (estimated, including clinical trials and approvals)
Manufacturing & Distribution	Lower marginal cost, benefits from scale
Marketing & Sales	Significant investment depending on geographic expansion
Profitability Timeline	Break-even anticipated post-2024 as revenues grow and market share stabilizes

---

4. Competitive Analysis: Zeposia vs. Market Alternatives

Attribute	Zeposia (Ozanimod)	First-Gen S1P Modyulators (e.g., Fingolimod)	Biologics (e.g., Ocrevus, Tysabri)
Route of Administration	Oral	Oral	IV or SC
Safety Profile	Favorable, lower PML risk	Risk of cardiovascular effects, PML risk	High efficacy, but with immune suppression
Efficacy	Comparable or superior in some studies	Established efficacy	Often higher, but with increased risks
Payer Acceptance	Moderate initial, growing	Established, but safety concerns	High, but costly

5. Key Opportunities and Challenges

Opportunities	Challenges
Expanded global regulatory approvals	Competition from established MS drugs
Growing UC market offering cross-indication revenue	Patent expirations on existing therapies
Increases in physician familiarity and patient acceptance	Potential adverse events and safety concerns as usage grows
Combination therapies with other MS and IBD treatments	Managing reimbursement and pricing pressures

---

6. Strategic Outlook

Strategy Element	Outlook
Market Penetration	Accelerate adoption via clinician education, showcasing real-world effectiveness
Geographic Expansion	Focus on Europe, Japan, and Asia-Pacific markets
Product Lifecycle Management	Develop next-generation formulations or combination therapies
Pricing & Partnering	Engage payers for value-based contracts and expand collaborations

---

7. Comparative Summary Table

Metrics / Features	Zeposia (Ozanimod)	Key Competitors
FDA Approval Year	2020 (MS), 2021 (UC)	Gilenya (2010), Tysabri (2004), Ocrevus (2017)
Indications	MS, UC	MS, UC, Crohn’s, other autoimmune diseases
Mechanism	Selective S1P receptor modulation	Various (JAK inhibitors, biologics, first-gen S1Ps)
Global Approvals	US, EU, Japan	Similar; Gilenya approved worldwide
Pricing Range	~$80,000–$90,000/year	Similar for oral therapies; biologics higher
Market Share (Estimate, 2022)	10-15% (MS)	Gilenya (~45%), others vary

---

8. Key Takeaways

• Market positioning: Zeposia benefits from a favorable safety profile, positioning it as a preferred oral agent against earlier-generation S1P modulators.
• Revenue potential: Projected to reach $1 billion+ globally by 2024, contingent on continued adoption, global expansion, and expanding indications.
• Competitive landscape: Faces stiff competition from biologics and other oral therapies; differentiation emphasizes safety, convenience, and cost-effectiveness.
• Global prospects: Regulatory approvals in key territories bolster future revenue streams.
• Strategic focus: Emphasize physician education, payer negotiations, and pipeline development to sustain growth.

---

9. FAQs

Q1: How does Zeposia compare to Gilenya in terms of safety?
Zeposia has a more selective S1P receptor profile, resulting in a lower risk of cardiovascular side effects and PML compared to first-generation agents like Gilenya. This safety advantage facilitates broader patient and physician acceptance.

Q2: What are the main barriers to Zeposia’s market growth?
Challenges include intense competition from established therapies, payer restrictions, and its relatively recent approval limiting physician familiarity. Gaining access to global markets also depends on regulatory approvals.

Q3: What is the outlook for Zeposia in the UC market?
With FDA approval since May 2021, the UC indication offers an additional revenue pipeline. Use is currently off-label in some regions, but post-approval strategies include direct marketing and clinician education.

Q4: Are there any combination therapy opportunities for Zeposia?
Potential exists, especially in MS, combining Zeposia with agents targeting complementary pathways. However, ongoing clinical trials are needed to confirm safety and efficacy.

Q5: What is the patent status of Zeposia?
Patent protection is expected until mid-2030s, providing exclusivity and pricing leverage. Patent challenges, if any, could influence long-term revenue trajectories.

---

References

1. FDA. (2020). Zeposia (ozanimod) approval letter.
2. Eli Lilly. (2021). Market analysis of MS and UC therapies.
3. National MS Society. (2022). MS prevalence estimates.
4. Centers for Disease Control and Prevention (CDC). (2022). UC prevalence report.
5. Bristol-Myers Squibb. (2022). Investor presentation on Zeposia.
6. European Medicines Agency (EMA). (2021). Zeposia EU approval summary.

---

In conclusion, Zeposia's market trajectory hinges on its safety profile, expanded indications, strategic market expansion, and competitive positioning. As a key entrant in the oral MS therapeutics landscape, it offers significant revenue prospects while facing competitive, regulatory, and adoption hurdles. Careful navigation of these dynamics will determine its long-term success in the evolving pharmaceutical industry.